Innovative drug concept stocks are mostly trading higher. SKB BIO (06990) is up 8.62% at HK$428.4. REMEGEN (09995) has gained 8.11% to HK$75.3. INNOCARE (09969) rose 6.67% to HK$11.04. IMMUNOTECH-B (06978) increased by 6.21% to HK$59. HENGRUI PHARMA (01276) is up 5.23% at HK$55.3.
The positive momentum follows recent data. In the first quarter of this year, the total value of China's innovative drug out-licensing deals exceeded $60 billion, indicating that overseas expansion has evolved from sporadic major deals into a sustainable industry capability. Furthermore, the number and academic caliber of Chinese studies selected for the ASCO 2026 conference continue to rise.
Market Analysis and Outlook
Analysts have weighed in on the sector's trajectory. Galaxy Securities noted that the healthcare sector as a whole experienced a downward trend in the first half of the year. The innovative drug segment, particularly Hong Kong-listed stocks, was impacted by geopolitical tensions and expectations around U.S. Federal Reserve interest rates, leading to a trend-driven decline. Valuations for both innovative and non-innovative drug companies have fallen to historically low levels. For the second half of the year, the focus will be on variables such as national medical insurance negotiations and the realization of clinical data from innovative drugs. The investment strategy involves seeking out true technological leaders in healthcare and considering companies' cash value.
Citic Securities also commented, stating that the underlying growth trend for the innovative drug industry remains intact. Recent short-term adjustments in capital flows have built up potential for upward movement. Several innovative drug trial readouts have been announced recently, alongside significant business development deals, providing continuous event-driven catalysts. The global competitiveness of China's innovative drugs continues to strengthen, and the fundamental industry logic of policy support and commercial profitability realization remains unchanged. Current out-licensing deals often involve partnerships for overseas rights to specific drug candidates, which is a preferred strategy for companies to accelerate global market expansion before establishing their own overseas sales capabilities. The increasing number of co-development and co-commercialization models reflects the growing competitiveness and bargaining power of Chinese innovative drug firms.